cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.2074342.v2
title: Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies

description: <b>Background</b>: Beneficial effects of vegetarian and vegan diets on health outcomes have been supposed in previous studies. <b>Objectives</b>: Aim of this study was to clarify the association between vegetarian, vegan diets, risk factors for chronic diseases, risk of all-cause mortality, incidence, and mortality from cardio-cerebrovascular diseases, total cancer and specific type of cancer (colorectal, breast, prostate and lung), through meta-analysis. <b>Methods</b>: A comprehensive search of Medline, EMBASE, Scopus, The Cochrane Library, and Google Scholar was conducted. <b>Results</b>: Eighty-six cross-sectional and 10 cohort prospective studies were included. The overall analysis among cross-sectional studies reported significant reduced levels of body mass index, total cholesterol, LDL-cholesterol, and glucose levels in vegetarians and vegans versus omnivores. With regard to prospective cohort studies, the analysis showed a significant reduced risk of incidence and/or mortality from ischemic heart disease (RR 0.75; 95% CI, 0.68 to 0.82) and incidence of total cancer (RR 0.92; 95% CI 0.87 to 0.98) but not of total cardiovascular and cerebrovascular diseases, all-cause mortality and mortality from cancer. No significant association was evidenced when specific types of cancer were analyzed. The analysis conducted among vegans reported significant association with the risk of incidence from total cancer (RR 0.85; 95% CI, 0.75 to 0.95), despite obtained only in a limited number of studies. <b>Conclusions</b>: This comprehensive meta-analysis reports a significant protective effect of a vegetarian diet versus the incidence and/or mortality from ischemic heart disease (−25%) and incidence from total cancer (−8%). Vegan diet conferred a significant reduced risk (−15%) of incidence from total cancer.
DOI: 10.6084/m9.figshare.2951263.v462
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074342.v1
title: Vegetarian, vegan diets and multiple health outcomes: a systematic review with meta-analysis of observational studies

description: <b>Background</b>: Beneficial effects of vegetarian and vegan diets on health outcomes have been supposed in previous studies. <b>Objectives</b>: Aim of this study was to clarify the association between vegetarian, vegan diets, risk factors for chronic diseases, risk of all-cause mortality, incidence and mortality from cardio-cerebrovascular diseases, total cancer and specific type of cancer (colorectal, breast, prostate and lung), through meta-analysis. <b>Methods</b>: A comprehensive search of Medline, EMBASE, Scopus, The Cochrane Library and Google Scholar was conducted. <b>Results</b>: Eighty-six cross-sectional and 10 cohort prospective studies were included. The overall analysis among cross-sectional studies reported significant reduced levels of body mass index, total cholesterol, LDL-cholesterol, and glucose levels in vegetarians and vegans versus omnivores. With regard to prospective cohort studies, the analysis showed a significant reduced risk of incidence and/or mortality from ischemic heart disease (RR 0.75; 95% CI, 0.68 to 0.82) and incidence of total cancer (RR 0.92; 95% CI 0.87 to 0.98) but not of total cardiovascular and cerebrovascular diseases, all-cause mortality and mortality from cancer. No significant association was evidenced when specific types of cancer were analyzed. The analysis conducted among vegans reported significant association with the risk of incidence from total cancer (RR 0.85; 95% CI, 0.75 to 0.95), despite obtained only in a limited number of studies. <b>Conclusions</b>: This comprehensive meta-analysis reports a significant protective effect of a vegetarian diet versus the incidence and/or mortality from ischemic heart disease (−25%) and incidence from total cancer (−8%). Vegan diet conferred a significant reduced risk (−15%) of incidence from total cancer.
DOI: 10.6084/m9.figshare.2951263.v463
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2951263.v464
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074285
title: Raport z analizy bibliometrycznej: „Pamiętnik Literacki” i „Diametros – An Online Journal of Philosophy”

description: Niniejszy materiał raport uzupełnienie do artykułu "Polski Współczynnik Wpływu a kultura cytowań w humanistyce".
DOI: 10.6084/m9.figshare.2951263.v465
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074267
title: Supporting information- PONE-D-15-46508R1.xls

description: This dataset consist of 774 Chinese citizens' decisions on sharing their personal information on 30 requests, and the information recipient is family member, friends, strangers, or none. Multiple-selection is allowed. The attributes include citizens' start time and finish time of answering the 30 requests, IP address, citizens' information e.g., gender, age, and major/work, and with whom the citizens agree to share the 30 personal information.
DOI: 10.6084/m9.figshare.2074267.v1
title: Supporting information- PONE-D-15-46508R1.xls

description: This dataset consist of 774 Chinese citizens' decisions on sharing their personal information on 30 requests, and the information recipient is family member, friends, strangers, or none. Multiple-selection is allowed. The attributes include citizens' start time and finish time of answering the 30 requests, IP address, citizens' information e.g., gender, age, and major/work, and with whom the citizens agree to share the 30 personal information.
DOI: 10.6084/m9.figshare.2951263.v466
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074285.v1
title: „Pamiętnik Literacki” i „Diametros – An Online Journal of Philosophy”

description: Niniejszy materiał raport uzupełnienie do artykułu "Polski Współczynnik Wpływu a kultura cytowań w humanistyce"
DOI: 10.6084/m9.figshare.2951263.v467
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074264
title: Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes

description: <b>Background</b> Lung cancer is the most common type of cancer in the world and is associated with significant mortality. Nivolumab demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients with advanced squamous non-small cell lung cancer (NSCLC) who were previously treated. The cost-effectiveness of nivolumab has not been assessed in Canada. A contentious component of projecting long-term cost and outcomes in cancer relates to the modeling approach adopted, with the two most common approaches being partitioned survival (PS) and Markov models. The objectives of this analysis were to estimate the cost-utility of nivolumab and to compare the results using these alternative modeling approaches. <b>Methods</b> Both PS and Markov models were developed using docetaxel and erlotinib as comparators. A three-health state model was used consisting of progression-free, progressed disease, and death. Disease progression and time to progression were estimated by identifying best-fitting survival curves from the clinical trial data for PFS and OS. Expected costs and health outcomes were calculated by combining health-state occupancy with medical resource use and quality-of-life assigned to each of the three health states. The health outcomes included in the model were survival and quality-adjusted-life-years (QALYs). <b>Results</b> Nivolumab was found to have the highest expected per-patient cost, but also improved per-patient life years (LYs) and QALYs. Nivolumab cost an additional $151,560 and $140,601 per QALY gained compared to docetaxel and erlotinib, respectively, using a PS model approach. The cost-utility estimates using a Markov model were very similar ($152,229 and $141,838, respectively, per QALY gained). <b>Conclusions</b> Nivolumab was found to involve a trade-off between improved patient survival and QALYs, and increased cost. It was found that the use of a PS or Markov model produced very similar estimates of expected cost, outcomes, and incremental cost-utility.
DOI: 10.6084/m9.figshare.2074285.v2
title: Report z analizy bibliometrycznej. „Pamiętnik Literacki” i „Diametros – An Online Journal of Philosophy”

description: Niniejszy materiał raport uzupełnienie do artykułu "Polski Współczynnik Wpływu a kultura cytowań w humanistyce"
DOI: 10.6084/m9.figshare.2074264.v2
title: Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes

description: <b>Background</b> Lung cancer is the most common type of cancer in the world and is associated with significant mortality. Nivolumab demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients with advanced squamous non-small cell lung cancer (NSCLC) who were previously treated. The cost-effectiveness of nivolumab has not been assessed in Canada. A contentious component of projecting long-term cost and outcomes in cancer relates to the modeling approach adopted, with the two most common approaches being partitioned survival (PS) and Markov models. The objectives of this analysis were to estimate the cost-utility of nivolumab and to compare the results using these alternative modeling approaches. <b>Methods</b> Both PS and Markov models were developed using docetaxel and erlotinib as comparators. A three-health state model was used consisting of progression-free, progressed disease, and death. Disease progression and time to progression were estimated by identifying best-fitting survival curves from the clinical trial data for PFS and OS. Expected costs and health outcomes were calculated by combining health-state occupancy with medical resource use and quality-of-life assigned to each of the three health states. The health outcomes included in the model were survival and quality-adjusted-life-years (QALYs). <b>Results</b> Nivolumab was found to have the highest expected per-patient cost, but also improved per-patient life years (LYs) and QALYs. Nivolumab cost an additional $151,560 and $140,601 per QALY gained compared to docetaxel and erlotinib, respectively, using a PS model approach. The cost-utility estimates using a Markov model were very similar ($152,229 and $141,838, respectively, per QALY gained). <b>Conclusions</b> Nivolumab was found to involve a trade-off between improved patient survival and QALYs, and increased cost. It was found that the use of a PS or Markov model produced very similar estimates of expected cost, outcomes, and incremental cost-utility.
DOI: 10.6084/m9.figshare.2074285.v4
title: Raport z analizy bibliometrycznej: „Pamiętnik Literacki” i „Diametros – An Online Journal of Philosophy”

description: Niniejszy materiał raport uzupełnienie do artykułu "Polski Współczynnik Wpływu a kultura cytowań w humanistyce".
DOI: 10.6084/m9.figshare.2951263.v468
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074264.v1
title: Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modelling approaches to estimate and extrapolate survival outcomes

description: <b>Background:</b> Lung cancer is the most common type of cancer in the world and is associated with significant mortality. Nivolumab demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients with advanced squamous non-small cell lung cancer (NSCLC) who were previously treated. The cost-effectiveness of nivolumab has not been assessed in Canada. A contentious component of projecting long-term cost and outcomes in cancer relates to the modelling approach adopted, with the two most common approaches being partitioned survival (PS) and Markov models. The objectives of this analysis were to estimate the cost-utility of nivolumab and to compare the results using these alternative modelling approaches. <b>Methods:</b> Both PS and Markov models were developed using docetaxel and erlotinib as comparators. A three-health state model was used consisting of progression-free, progressed disease, and death. Disease progression and time to progression were estimated by identifying best-fitting survival curves from the clinical trial data for PFS and OS. Expected costs and health outcomes were calculated by combining health-state occupancy with medical resource use and quality of life assigned to each of the three health states. The health outcomes included in the model were survival and quality-adjusted-life-years (QALYs). <b>Results:</b> Nivolumab was found to have the highest expected per-patient cost, but also improved per -patient life years and QALYs. Nivolumab cost an additional $151,560 and $140,601 per QALY gained compared to docetaxel and erlotinib using a PS model approach. The cost-utility estimates using a Markov model were very similar ($152,229 and $141,838 per QALY gained). <b>Conclusions:</b> Nivolumab was found to involve a trade-off between improved patient survival and QALYs, and increased cost. It was found that the use of a PS or Markov model produced very similar estimates of expected cost, outcomes and incremental cost-utility.
DOI: 10.6084/m9.figshare.2074252
title: AtHESPERIN: a novel regulator of circadian rhythms with poly(A)-degrading activity in plants

description: We report the identification and characterization of a novel gene, <i>AtHesperin</i> (<i>AtHESP</i>) that codes for a deadenylase in <i>Arabidopsis thaliana</i>. The gene is under circadian clock-gene regulation and has similarity to the mammalian <i>Nocturnin</i>. AtHESP can efficiently degrade poly(A) substrates exhibiting allosteric kinetics. Size exclusion chromatography and native electrophoresis coupled with kinetic analysis support that the native enzyme is oligomeric with at least 3 binding sites. Knockdown and overexpression of <i>AtHESP</i> in plant lines affects the expression and rhythmicity of the clock core oscillator genes <i>TOC1</i> and <i>CCA1</i>. This study demonstrates an evolutionary conserved poly(A)-degrading activity in plants and suggests deadenylation as a mechanism involved in the regulation of the circadian clock. A role of <i>AtHESP</i> in stress response in plants is also depicted.
DOI: 10.6084/m9.figshare.2074252.v1
title: AtHESPERIN: a novel regulator of circadian rhythms with poly(A)-degrading activity in plants

description: We report the identification and characterization of a novel gene, <i>AtHesperin</i> (<i>AtHESP</i>) that codes for a deadenylase in <i>Arabidopsis thaliana</i>. The gene is under circadian clock-gene regulation and has similarity to the mammalian <i>Nocturnin</i>. AtHESP can efficiently degrade poly(A) substrates exhibiting allosteric kinetics. Size exclusion chromatography and native electrophoresis coupled with kinetic analysis support that the native enzyme is oligomeric with at least 3 binding sites. Knockdown and overexpression of <i>AtHESP</i> in plant lines affects the expression and rhythmicity of the clock core oscillator genes <i>TOC1</i> and <i>CCA1</i>. This study demonstrates an evolutionary conserved poly(A)-degrading activity in plants and suggests deadenylation as a mechanism involved in the regulation of the circadian clock. A role of <i>AtHESP</i> in stress response in plants is also depicted.
DOI: 10.6084/m9.figshare.2074285.v3
title: Raport z analizy bibliometrycznej: „Pamiętnik Literacki” i „Diametros – An Online Journal of Philosophy”

description: Niniejszy materiał raport uzupełnienie do artykułu "Polski Współczynnik Wpływu a kultura cytowań w humanistyce"
DOI: 10.6084/m9.figshare.2951263.v469
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074231
title: Supplementary BEAST XML files for our paper 'Bayesian codon substitution modeling to identify sources of pathogen evolutionary rate variation'.

description: BEAST XML files containing the data and the selected models needed to recreate the results we present in Figures 1 through 4 of our paper.
DOI: 10.6084/m9.figshare.2951263.v470
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074231.v1
title: BatRabies_2_Epoch_Model_Fig4.xml

description: BEAST XML file containing the data and the selected models needed to recreate the results we present in Figure 4 of our paper.
DOI: 10.6084/m9.figshare.2951263.v471
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.
DOI: 10.6084/m9.figshare.2074111
title: <i>Sepia</i> from the Miocene of the Central Paratethys: new taxa and notes on late Cenozoic cuttlefish diversity

description: A new and locally abundant species of <i>Sepia</i>, <i>S. juliebarborarum</i> sp. nov., and single records of <i>S</i>. aff. <i>loerentheyi</i> and <i>S</i>. aff. <i>sanctacrucensis</i> from the upper Badenian of Slovakia and Austria, <i>S. mikuzi</i> sp. nov., <i>S.</i> aff. <i>mikuzi</i> sp. nov. and <i>Sepia</i> sp. from the middle Badenian of Slovenia, document a greater Miocene sepiid diversity in the Central Paratethys than previously recorded. In the present study, Miocene sepiids from the Central Paratethys are systematically revised and, in part, compared to other coeval taxa from elsewhere. Middle Miocene diversity in the Central Paratethys amounts to nine species, inclusive of four taxa retained in open nomenclature. Here we use the morphology of the dorsal shield and septal suture lines as key features for systematic assignment at the species level. Usage of the generic name <i>Sepia</i> for these Miocene sepiids is corroborated by uniquely preserved material of <i>S</i>. <i>vindobonensis</i> from the middle Badenian of Austria. This reveals only minor morphological differences during ontogeny from the Recent type species of <i>Sepia</i>, <i>S</i>. <i>officinalis</i>. The stratigraphical range of sepiids in the Central Paratethys is reinterpreted and shown to be early to late Badenian. Miocene <i>Sepia</i> diversity in the Central Paratethys is greater than previously supposed, which supports normal marine conditions and an open connection with the Mediterranean. http://zoobank.org/urn:lsid:zoobank.org:pub:3B32BA47-EB28-4A75-95FE-6349C08BB5EA.
DOI: 10.6084/m9.figshare.2074111.v1
title: <i>Sepia</i> from the Miocene of the Central Paratethys: new taxa and notes on late Cenozoic cuttlefish diversity

description: A new and locally abundant species of <i>Sepia</i>, <i>S. juliebarborarum</i> sp. nov., and single records of <i>S</i>. aff. <i>loerentheyi</i> and <i>S</i>. aff. <i>sanctacrucensis</i> from the upper Badenian of Slovakia and Austria, <i>S. mikuzi</i> sp. nov., <i>S.</i> aff. <i>mikuzi</i> sp. nov. and <i>Sepia</i> sp. from the middle Badenian of Slovenia, document a greater Miocene sepiid diversity in the Central Paratethys than previously recorded. In the present study, Miocene sepiids from the Central Paratethys are systematically revised and, in part, compared to other coeval taxa from elsewhere. Middle Miocene diversity in the Central Paratethys amounts to nine species, inclusive of four taxa retained in open nomenclature. Here we use the morphology of the dorsal shield and septal suture lines as key features for systematic assignment at the species level. Usage of the generic name <i>Sepia</i> for these Miocene sepiids is corroborated by uniquely preserved material of <i>S</i>. <i>vindobonensis</i> from the middle Badenian of Austria. This reveals only minor morphological differences during ontogeny from the Recent type species of <i>Sepia</i>, <i>S</i>. <i>officinalis</i>. The stratigraphical range of sepiids in the Central Paratethys is reinterpreted and shown to be early to late Badenian. Miocene <i>Sepia</i> diversity in the Central Paratethys is greater than previously supposed, which supports normal marine conditions and an open connection with the Mediterranean. http://zoobank.org/urn:lsid:zoobank.org:pub:3B32BA47-EB28-4A75-95FE-6349C08BB5EA.
DOI: 10.6084/m9.figshare.2951263.v472
title: UNH-RVAT 3-D Spalart--Allmaras RANS simulation results

description: Results from simulating the UNH-RVAT cross-flow turbine in three dimensions with the Spalart--Allmaras RANS model in OpenFOAM 2.3.x (590d57f32fed). See link below for case files (note: use the `SpalartAllmaras` branch), which include a script for downloading and extracting, as well as scripts for post-processing.